BillionToOne Stock
BillionToOne is a precision diagnostics company that makes molecular diagnostics accurate, efficient, and accessible for all.
Sign up today and learn more about BillionToOne Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About BillionToOne Stock
BillionToOne is a precision diagnostics company that quantifies biology to create molecular diagnostics accurate, efficient, and accessible for all. The company's patent-pending molecular counter platform is a technology platform that can accurately count the DNA molecules to the single-count level. BillionToOne's mission is to make pre-natal testing safe and affordable for every expecting mother. Its novel technology can detect even single-gene disorders such as thalassemia through a simple blood test. They are replacing amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test, starting with developing countries. BillionToOne was founded in 2016 and is headquartered in Menlo Park, California.
Funding History
August 2017 | $120K |
---|---|
September 2017 | $2.4M |
March 2019 | $15.0M |
March 2020 | $15.0M |
Management
Co-Founder
Oguzhan Atay
CTO
David Tsao
Head of Marketing
Oscar Cabot
Press
patents - Apr, 15 2024
Sequencing Output Determination and Analysis with Target-Associated Molecules …patents - Apr, 15 2024
Fragment analysis for quantitative diagnostics of biological targetspatents - Apr, 15 2024
Non-invasive prenatal testing at early stage of pregnancypatents - Apr, 15 2024
Target-associated molecules for characterization associated with biological …patents - Apr, 15 2024
Molecule counting of methylated cell-free dna for treatment monitoring